NASDAQ:VERV Verve Therapeutics (VERV) Stock Price, News & Analysis → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free VERV Stock Alerts $13.28 +0.09 (+0.68%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$12.96▼$13.6350-Day Range$10.81▼$17.9652-Week Range$8.22▼$21.42Volume647,590 shsAverage Volume1.08 million shsMarket Capitalization$1.11 billionP/E RatioN/ADividend YieldN/APrice Target$34.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Verve Therapeutics alerts: Email Address Verve Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside159.0% Upside$34.40 Price TargetShort InterestBearish25.73% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.20Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.04) to ($3.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.80 out of 5 starsMedical Sector691st out of 938 stocksPharmaceutical Preparations Industry314th out of 423 stocks 3.4 Analyst's Opinion Consensus RatingVerve Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.40, Verve Therapeutics has a forecasted upside of 159.0% from its current price of $13.28.Amount of Analyst CoverageVerve Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted25.73% of the float of Verve Therapeutics has been sold short.Short Interest Ratio / Days to CoverVerve Therapeutics has a short interest ratio ("days to cover") of 12.8, which indicates bearish sentiment.Change versus previous monthShort interest in Verve Therapeutics has recently increased by 12.62%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVerve Therapeutics does not currently pay a dividend.Dividend GrowthVerve Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VERV. Previous Next 4.0 News and Social Media Coverage News SentimentVerve Therapeutics has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Verve Therapeutics this week, compared to 3 articles on an average week.Search Interest20 people have searched for VERV on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows7 people have added Verve Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verve Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders21.40% of the stock of Verve Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.11% of the stock of Verve Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Verve Therapeutics are expected to decrease in the coming year, from ($3.04) to ($3.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verve Therapeutics is -4.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verve Therapeutics is -4.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerve Therapeutics has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Verve Therapeutics Stock (NASDAQ:VERV)Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Read More VERV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VERV Stock News HeadlinesMarch 28, 2024 | globenewswire.comVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)March 27, 2024 | msn.com7 Best Gene-Editing Stocks to Invest in Right NowMarch 29, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.March 24, 2024 | americanbankingnews.comVerve Therapeutics, Inc. (NASDAQ:VERV) Receives Average Rating of "Moderate Buy" from AnalystsMarch 21, 2024 | investorplace.com3 Stocks That Could Be the Next Big Thing in Gene EditingMarch 12, 2024 | msn.com'In Vivo' Gene Editing: Adjusting DNA Inside the Body Is Groundbreaking, but Still RiskyMarch 11, 2024 | msn.comDoctors Can Now Edit the Genes Inside Your BodyMarch 1, 2024 | globenewswire.comVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)March 29, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… February 29, 2024 | finance.yahoo.comNew Forecasts: Here's What Analysts Think The Future Holds For Verve Therapeutics, Inc. (NASDAQ:VERV)February 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verve Therapeutics Amidst Promising Clinical Studies and Strategic AdvancementsFebruary 28, 2024 | finance.yahoo.comVerve Therapeutics Full Year 2023 Earnings: Beats ExpectationsFebruary 27, 2024 | finance.yahoo.comVerve Therapeutics Inc (VERV) Reports Progress and Financials for Q4 and Full Year 2023February 27, 2024 | msn.comBeam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing DrugFebruary 27, 2024 | benzinga.comVerve Therapeutics: Q4 Earnings InsightsFebruary 27, 2024 | marketwatch.comVerve Therapeutics Shares Gain 16% On 4Q Revenue BeatFebruary 27, 2024 | msn.comVerve Therapeutics GAAP EPS of -$0.69 beats by $0.13, revenue of $5.14M beats by $3.97MFebruary 27, 2024 | globenewswire.comVerve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 25, 2024 | edition.cnn.comBeam Therapeutics, Inc.February 19, 2024 | investorplace.com3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough PotentialFebruary 13, 2024 | bizjournals.comVerve Therapeutics co-founder named GV’s new GPFebruary 12, 2024 | seekingalpha.comVerve's Proof-Of-Concept Data Doesn't Inspire ConfidenceFebruary 12, 2024 | benzinga.comVerve Therapeutics Stock (NASDAQ:VERV) Dividends: History, Yield and DatesFebruary 8, 2024 | investing.comVerve Therapeutics Inc (VERV)February 1, 2024 | finance.yahoo.comVerve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceJanuary 29, 2024 | finance.yahoo.comVerve Therapeutics, Inc. (NASDAQ:VERV) is a favorite amongst institutional investors who own 64%January 19, 2024 | finance.yahoo.com3 Stocks to Buy in the Booming Field of Gene EditingSee More Headlines Receive VERV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today3/29/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VERV CUSIPN/A CIK1840574 Webvervetx.com Phone617-603-0070FaxN/AEmployees255Year FoundedN/APrice Target and Rating Average Stock Price Target$34.40 High Stock Price Target$55.00 Low Stock Price Target$22.00 Potential Upside/Downside+159.0%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-200,070,000.00 Net Margins-1,701.70% Pretax Margin-1,699.21% Return on Equity-39.33% Return on Assets-30.92% Debt Debt-to-Equity RatioN/A Current Ratio17.24 Quick Ratio17.24 Sales & Book Value Annual Sales$11.76 million Price / Sales94.43 Cash FlowN/A Price / Cash FlowN/A Book Value$7.31 per share Price / Book1.82Miscellaneous Outstanding Shares83,620,000Free Float65,725,000Market Cap$1.11 billion OptionableOptionable Beta1.76 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Burt A. Adelman M.D. (Age 72)Co-Founder & Independent Chairman of the Board Comp: $87.55kDr. Sekar Kathiresan M.D. (Age 52)Co-Founder, CEO & Director Comp: $899.55kMr. Andrew D. Ashe J.D. (Age 57)President, COO & General Counsel Comp: $703.85kDr. Andrew Bellinger M.D. (Age 45)Ph.D., Chief Scientific Officer Comp: $703.85kDr. Kiran Musunuru M.D.M.P.H., Ph.D., Co-FounderDr. J. Keith Joung M.D.Ph.D., Co-FounderDr. Anthony Philippakis M.D.Ph.D., Co-Founder & Scientific Advisory Board MemberDr. Barry S. Ticho FACC (Age 63)M.D., Ph.D., Co-Founder Mr. Issi Rozen M.B.A.Co-Founder & Strategic AdvisorMs. Allison Dorval (Age 48)CFO & Principal Accounting Officer Comp: $260.93kMore ExecutivesKey CompetitorsCentessa PharmaceuticalsNASDAQ:CNTA89bioNASDAQ:ETNBSage TherapeuticsNASDAQ:SAGEZentalis PharmaceuticalsNASDAQ:ZNTLMirum PharmaceuticalsNASDAQ:MIRMView All CompetitorsInsiders & InstitutionsNewbridge Financial Services Group Inc.Bought 2,182 shares on 3/28/2024Ownership: 0.003%Nomura Holdings Inc.Bought 900 shares on 3/27/2024Ownership: 0.023%PNC Financial Services Group Inc.Bought 2,094 shares on 3/22/2024Ownership: 0.003%Vanguard Group Inc.Bought 638,962 shares on 3/11/2024Ownership: 6.544%PBCay One RSC LtdBought 6,864 shares on 3/5/2024Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions VERV Stock Analysis - Frequently Asked Questions Should I buy or sell Verve Therapeutics stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verve Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VERV shares. View VERV analyst ratings or view top-rated stocks. What is Verve Therapeutics' stock price target for 2024? 7 analysts have issued 12 month price targets for Verve Therapeutics' stock. Their VERV share price targets range from $22.00 to $55.00. On average, they predict the company's stock price to reach $34.40 in the next year. This suggests a possible upside of 159.0% from the stock's current price. View analysts price targets for VERV or view top-rated stocks among Wall Street analysts. How have VERV shares performed in 2024? Verve Therapeutics' stock was trading at $13.94 at the start of the year. Since then, VERV shares have decreased by 4.7% and is now trading at $13.28. View the best growth stocks for 2024 here. When is Verve Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our VERV earnings forecast. How were Verve Therapeutics' earnings last quarter? Verve Therapeutics, Inc. (NASDAQ:VERV) issued its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.69) EPS for the quarter, beating analysts' consensus estimates of ($0.83) by $0.14. The company had revenue of $5.14 million for the quarter, compared to analyst estimates of $3.95 million. Verve Therapeutics had a negative net margin of 1,701.70% and a negative trailing twelve-month return on equity of 39.33%. What ETFs hold Verve Therapeutics' stock? ETFs with the largest weight of Verve Therapeutics (NASDAQ:VERV) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), ARK Genomic Revolution ETF (ARKG), Direxion Moonshot Innovators ETF (MOON), Global X Genomics & Biotechnology ETF (GNOM), WisdomTree BioRevolution Fund (WDNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and ARK Innovation ETF (ARKK).iShares Micro-Cap ETF (IWC). When did Verve Therapeutics IPO? Verve Therapeutics (VERV) raised $201 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 11,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair acted as the underwriters for the IPO. Who are Verve Therapeutics' major shareholders? Verve Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (11.02%), Vanguard Group Inc. (8.58%), Vanguard Group Inc. (6.54%), Federated Hermes Inc. (6.24%), Sumitomo Mitsui Trust Holdings Inc. (3.76%) and Nikko Asset Management Americas Inc. (3.76%). Insiders that own company stock include 2017 Gp LLC Gv, Allison Dorval, Andrew Bellinger, Andrew D Ashe, Burt A Adelman, Cormorant Asset Management, Lp, Fmr Llc, Krishna Yeshwant, Logos Global Management Lp and Sekar Kathiresan. View institutional ownership trends. How do I buy shares of Verve Therapeutics? Shares of VERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VERV) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.